Citations (106)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (20)
Jun-Chen Liu & Hong-Jing Yu. (2023) A Review of the Pharmacokinetic Characteristics of Immune Checkpoint Inhibitors and Their Clinical Impact Factors. Pharmacogenomics and Personalized Medicine 16, pages 29-36.
Read now
Read now
Karelle Ménochet, Hongbin Yu, Bonnie Wang, Jay Tibbitts, Cheng-Pang Hsu, Amrita V. Kamath, Wolfgang F. Richter & Andreas Baumann. (2022) Non-human primates in the PKPD evaluation of biologics: Needs and options to reduce, refine, and replace. A BioSafe White Paper. mAbs 14:1.
Read now
Read now
Catherine Rowan, Ryan Ungaro, Saurabh Mehandru & Jean-Frederic Colombel. (2022) An overview of ozanimod as a therapeutic option for adults with moderate-to-severe active ulcerative colitis. Expert Opinion on Pharmacotherapy 23:8, pages 893-904.
Read now
Read now
Wayne L Furman. (2021) Monoclonal Antibody Therapies for High Risk Neuroblastoma. Biologics: Targets and Therapy 15, pages 205-219.
Read now
Read now
Lu Gaohua, Xiusheng Miao & Liu Dou. (2021) Crosstalk of physiological pH and chemical pKa under the umbrella of physiologically based pharmacokinetic modeling of drug absorption, distribution, metabolism, excretion, and toxicity. Expert Opinion on Drug Metabolism & Toxicology 17:9, pages 1103-1124.
Read now
Read now
Eva Germovsek, Ming Cheng & Craig Giragossian. (2021) Allometric scaling of therapeutic monoclonal antibodies in preclinical and clinical settings. mAbs 13:1.
Read now
Read now
Daniela Gilardi, Roberto Gabbiadini, Mariangela Allocca, Carmen Correale, Gionata Fiorino, Federica Furfaro, Alessandra Zilli, Laurent Peyrin-Biroulet & Silvio Danese. (2020) PK, PD, and interactions: the new scenario with JAK inhibitors and S1P receptor modulators, two classes of small molecule drugs, in IBD. Expert Review of Gastroenterology & Hepatology 14:9, pages 797-806.
Read now
Read now
Rong Deng, Chenguang Zhou, Dongwei Li, Hao Cai, Siddharth Sukumaran, Montserrat Carrasco-Triguero, Ola Saad, Denise Nazzal, Christopher Lowe, Saroja Ramanujan & Amrita V. Kamath. (2019) Preclinical and translational pharmacokinetics of a novel THIOMAB™ antibody-antibiotic conjugate against Staphylococcus aureus. mAbs 11:6, pages 1162-1174.
Read now
Read now
Maria Gabriella Matera, Paola Rogliani, Luigino Calzetta & Mario Cazzola. (2018) Pharmacokinetic/pharmacodynamic profile of reslizumab in asthma. Expert Opinion on Drug Metabolism & Toxicology 14:2, pages 239-245.
Read now
Read now
Sharmila Rajan, Danielle Mandikian, Amos Baruch, Thomas R. Gelzleichter, Dale Stevens, Junichiro Sonoda, Kyra Cowan, C. Andrew Boswell & Eric Stefanich. (2017) Preclinical pharmacokinetic characterization of an adipose tissue-targeting monoclonal antibody in obese and non-obese animals. mAbs 9:8, pages 1379-1388.
Read now
Read now
Antoine Couture-Cossette, Alex Carignan, Subburaj Ilangumaran & Louis Valiquette. (2017) Bezlotoxumab for the prevention of Clostridium difficile recurrence. Expert Opinion on Biological Therapy 17:11, pages 1439-1445.
Read now
Read now
Ulrich Brinkmann & Roland E. Kontermann. (2017) The making of bispecific antibodies. mAbs 9:2, pages 182-212.
Read now
Read now
Chenguang Zhou, Sophie Lehar, Johnny Gutierrez, Carrie M. Rosenberger, Nina Ljumanovic, Jason Dinoso, Neelima Koppada, Kyu Hong, Amos Baruch, Montserrat Carrasco-Triguero, Ola Saad, Sanjeev Mariathasan & Amrita V. Kamath. (2016) Pharmacokinetics and pharmacodynamics of DSTA4637A: A novel THIOMAB™ antibody antibiotic conjugate against Staphylococcus aureus in mice. mAbs 8:8, pages 1612-1619.
Read now
Read now
Sirin Gandhi, Dejan Jakimovski, Rahil Ahmed, David Hojnacki, Channa Kolb, Bianca Weinstock-Guttman & Robert Zivadinov. (2016) Use of natalizumab in multiple sclerosis: current perspectives. Expert Opinion on Biological Therapy 16:9, pages 1151-1162.
Read now
Read now
Priyanka Gupta, Amrita V. Kamath, Summer Park, Henry Chiu, Jeff Lutman, Mauricio Maia, Man-Wah Tan, Min Xu, Lee Swem & Rong Deng. (2016) Preclinical pharmacokinetics of MHAA4549A, a human monoclonal antibody to influenza A virus, and the prediction of its efficacious clinical dose for the treatment of patients hospitalized with influenza A . mAbs 8:5, pages 991-997.
Read now
Read now
Renaud Respaud, Laurent Vecellio, Patrice Diot & Nathalie Heuzé-Vourc’h. (2015) Nebulization as a delivery method for mAbs in respiratory diseases. Expert Opinion on Drug Delivery 12:6, pages 1027-1039.
Read now
Read now
Maya K Leabman, Y Gloria Meng, Robert F Kelley, Laura E DeForge, Kyra J Cowan & Suhasini Iyer. (2013) Effects of altered FcγR binding on antibody pharmacokinetics in cynomolgus monkeys. mAbs 5:6, pages 896-903.
Read now
Read now
Vladimir Vexler, Li Yu, Chandrasena Pamulapati, Rosario Garrido, Hans Peter Grimm, Priya Sriraman, Sandhya Bohini, Michael Schraeml, Usha Singh, Michael Brandt, Stefan Ries, Han Ma, Klaus Klumpp & Changhua Ji. (2013) Target-mediated drug disposition and prolonged liver accumulation of a novel humanized anti-CD81 monoclonal antibody in cynomolgus monkeys. mAbs 5:5, pages 776-786.
Read now
Read now
Ryan J. Hansen, Robin M. Brown, Jirong Lu & Victor J. Wroblewski. (2013) Qualification of a free ligand assay in the presence of anti-ligand antibody Fab fragments. mAbs 5:2, pages 288-296.
Read now
Read now
E Michael Lewiecki. (2013) Monoclonal antibodies for the treatment of osteoporosis. Expert Opinion on Biological Therapy 13:2, pages 183-196.
Read now
Read now
Articles from other publishers (86)
Jiarui Chen, Rongfang Lin, Guimu Guo, Wanhong Wu, Meng Ke, Chengjie Ke, Pinfang Huang & Cuihong Lin. (2023) Physiologically‐Based Pharmacokinetic Modeling of Anti‐Tumor Necrosis Factor Agents for Inflammatory Bowel Disease Patients to Predict the Withdrawal Time in Pregnancy and Vaccine Time in Infants. Clinical Pharmacology & Therapeutics 114:6, pages 1254-1263.
Crossref
Crossref
Gizette Sperinde, Michael Dolton, Wenhui Zhang, Joel Mathews, Wendy Putnam & Saloumeh K Fischer. (2023) Factors contributing to the nonlinear pharmacokinetics of astegolimab: a close examination of potential causes. Bioanalysis 15:21, pages 1305-1314.
Crossref
Crossref
Lubna Abuqayyas, Po‐Wei Chen, Marcia Teixeira dos Santos, Jane R. Parnes, Sameer Doshi, Sandeep Dutta & Brett E. Houk. (2023)
Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Properties of Rozibafusp Alfa, a Bispecific Inhibitor of
BAFF
and
ICOSL
: Analyses of Phase I Clinical Trials
. Clinical Pharmacology & Therapeutics 114:2, pages 371-380.
Crossref
Crossref
Rajbharan Yadav, Siddharth Sukumaran, Jeff Lutman, Mayur S. Mitra, Wendy Halpern, Tianhe Sun, A. Francesca Setiadi, Margaret Neighbors, X. Rebecca Sheng, Victor Yip, Ben-Quan Shen, Chang Liu, Lyrialle Han, Ayse Meric Ovacik, Yan Wu, Sara Glickstein, Rebecca Kunder, Joseph R. Arron, Lin Pan, Amrita V. Kamath & Eric G. Stefanich. (2023) Utilizing PK and PD Biomarkers to Guide the First-in-Human Starting Dose Selection of MTBT1466A: A Novel Humanized Monoclonal Anti-TGFβ3 Antibody for the Treatment of Fibrotic Diseases. Journal of Pharmaceutical Sciences.
Crossref
Crossref
Ahizechukwu C. Eke, Rahel D. Gebreyohannes, Maria Fernanda Scantamburlo Fernandes & Venkateswaran C. Pillai. (2023) Physiologic Changes During Pregnancy and Impact on Small‐Molecule Drugs, Biologic (Monoclonal Antibody) Disposition, and Response. The Journal of Clinical Pharmacology 63:S1.
Crossref
Crossref
Hossam Nada, Aneesh Sivaraman, Qili Lu, Kyoungho Min, Sungdo Kim, Ja-Il Goo, Yongseok Choi & Kyeong Lee. (2023) Perspective for Discovery of Small Molecule IL-6 Inhibitors through Study of Structure–Activity Relationships and Molecular Docking. Journal of Medicinal Chemistry.
Crossref
Crossref
Stephanie N. Liu, Mathilde Marchand, Xiaoyan Liu, Gladys Ingle, Vidya Maiya, Vilma Graupner, Markus C. Elze, Phyllis Chan, Joy C. Hsu, Alyse Lin, Shweta Vadhavkar, Benjamin Wu & Rene Bruno. (2022) Extension of the Alternative Intravenous Dosing Regimens of Atezolizumab into Combination Settings through Modeling and Simulation. The Journal of Clinical Pharmacology 62:11, pages 1393-1402.
Crossref
Crossref
Lia Liefaard, Eva Hajduk, Frans van den Berg, Eirini Panoilia, Gerben Bouma, Edoardo Lisi, Naren Srinivasan, Yi Cui, Annette S. Gross, Ruth Tarzi & Daniel J.B. Marks. (2022) Randomized Trial of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK2831781 in Healthy Japanese and White Participants. Clinical Pharmacology in Drug Development 11:11, pages 1284-1293.
Crossref
Crossref
Blaise Pasquiers, Salih Benamara, Mathieu Felices, Laurent Nguyen & Xavier Declèves. (2022) Review of the Existing Translational Pharmacokinetics Modeling Approaches Specific to Monoclonal Antibodies (mAbs) to Support the First-In-Human (FIH) Dose Selection. International Journal of Molecular Sciences 23:21, pages 12754.
Crossref
Crossref
Wenpeng Zhang, Yanan Xiang, Lingchao Wang, Furun Wang, Guanglu Li & Xiaomei Zhuang. (2022) Translational pharmacokinetics of a novel bispecific antibody against Ebola virus (MBS77E) from animal to human by PBPK modeling & simulation. International Journal of Pharmaceutics 626, pages 122160.
Crossref
Crossref
Zvonimir Petric, Joao Goncalves & Paulo Paixao. (2022) Under the Umbrella of Clinical Pharmacology: Inflammatory Bowel Disease, Infliximab and Adalimumab, and a Bridge to an Era of Biosimilars. Pharmaceutics 14:9, pages 1766.
Crossref
Crossref
Jayaprakasam Bolleddula, Kevin Brady, Gerard Bruin, Anthony Lee, Jennifer A. Martin, Markus Walles, Keyang Xu, Tong-Yuan Yang, Xiaochun Zhu & Hongbin Yu. (2022) Absorption, Distribution, Metabolism, and Excretion of Therapeutic Proteins: Current Industry Practices and Future Perspectives. Drug Metabolism and Disposition 50:6, pages 837-845.
Crossref
Crossref
Man-Seok Ju, Hye-Mi Ahn, Seong-Gu Han, Sanghwan Ko, Jung-Hyun Na, Migyeong Jo, Chung Su Lim, Byoung Joon Ko, Yeon Gyu Yu, Won-Kyu Lee, Youn-Jae Kim & Sang Taek Jung. (2021) A human antibody against human endothelin receptor type A that exhibits antitumor potency. Experimental & Molecular Medicine 53:9, pages 1437-1448.
Crossref
Crossref
Yan Xin, Fengyan Xu, Yuying Gao, Nivedita Bhatt, Jason Chamberlain, Saba Sile, Suzy Hammel, Robert J. Holt & Srini Ramanathan. (2021) Pharmacokinetics and Exposure-Response Relationship of Teprotumumab, an Insulin-Like Growth Factor-1 Receptor-Blocking Antibody, in Thyroid Eye Disease. Clinical Pharmacokinetics 60:8, pages 1029-1040.
Crossref
Crossref
Marion Ferreira, Thomas Secher, Nathalie Heuze-Vourc’H & Karen L Reckamp. (2021) Immune Checkpoint and Anti-Angiogenic Antibodies for the Treatment of Non-Small Cell Lung Cancer in the European Union and United States. Pharmaceutics 13:6, pages 912.
Crossref
Crossref
Niurys de Castro-Suárez, Mirjam N. Trame, Mayra Ramos-Suzarte, José M. Dávalos, Raymed A. Bacallao-Mendez, Anaelys R. Maceo-Sinabele, Víctor Mangas-Sanjuán, Gledys Reynaldo-Fernández & Leyanis Rodríguez-Vera. (2020) Semi-Mechanistic Pharmacokinetic Model to Guide the Dose Selection of Nimotuzumab in Patients with Autosomal Dominant Polycystic Kidney Disease. Pharmaceutics 12:12, pages 1147.
Crossref
Crossref
Amina Bensalem & David Ternant. (2020) Pharmacokinetic Variability of Therapeutic Antibodies in Humans: A Comprehensive Review of Population Pharmacokinetic Modeling Publications. Clinical Pharmacokinetics 59:7, pages 857-874.
Crossref
Crossref
Sally Kelliny, Ho Yin Lam, Ankit Parikh, Yan-Jiang Wang, Larisa Bobrovskaya, Richard Upton & Xin-Fu Zhou. (2020) Preclinical Study of the Pharmacokinetics of p75ECD-Fc, a Novel Human Recombinant Protein for Treatment of Alzheimer’s Disease, in Sprague Dawley Rats. Current Drug Metabolism 21:3, pages 235-244.
Crossref
Crossref
Clément Bailly, Benjamin Chalopin, Sébastien Gouard, Thomas Carlier, Patricia Remaud-Le Saëc, Séverine Marionneau-Lambot, Philippe Moreau, Cyrille Touzeau, Françoise Kraeber-Bodere, Caroline Bodet-Milin & Michel Chérel. (2020) ImmunoPET in Multiple Myeloma—What? So What? Now What?. Cancers 12:6, pages 1467.
Crossref
Crossref
Mario RegazziJoseè Golay & Mariadelfina Molinaro. (2020) Monoclonal Antibody Monitoring: Clinically Relevant Aspects, A Systematic Critical Review. Therapeutic Drug Monitoring 42:1, pages 45-56.
Crossref
Crossref
Sherman Picardo & Cynthia H. Seow. (2020) The impact of pregnancy on biologic therapies for the treatment of inflammatory bowel disease. Best Practice & Research Clinical Gastroenterology 44-45, pages 101670.
Crossref
Crossref
Hussein M. Abdallah & Andy Z.X. Zhu. (2019) A Minimal Physiologically‐Based Pharmacokinetic Model Demonstrates Role of the Neonatal Fc Receptor (FcRn) Competition in Drug–Disease Interactions With Antibody Therapy. Clinical Pharmacology & Therapeutics 107:2, pages 423-434.
Crossref
Crossref
Junghwan Shin, Han-Joon Kim & Beomseok Jeon. (2020) Immunotherapy Targeting Neurodegenerative Proteinopathies: α-Synucleinopathies and Tauopathies. Journal of Movement Disorders 13:1, pages 11-19.
Crossref
Crossref
Robert S. Foti, Kaustav Biswas, Jennifer Aral, Xuhai Be, Loren Berry, Yuan Cheng, Kip Conner, James R. Falsey, Charles Glaus, Brad Herberich, Dean Hickman, Tayo Ikotun, Hongyan Li, Jason Long, Liyue Huang, Les P. Miranda, Justin Murray, Bryan Moyer, Chawita Netirojjanakul, Thomas E. Nixey, Kelvin Sham, Marcus Soto, Christopher M. Tegley, Linh Tran, Bin Wu, Lin Yin & Dan A. Rock. (2019) Use of Cryopreserved Hepatocytes as Part of an Integrated Strategy to Characterize In Vivo Clearance for Peptide-Antibody Conjugate Inhibitors of Nav1.7 in Preclinical Species. Drug Metabolism and Disposition 47:10, pages 1111-1121.
Crossref
Crossref
Chunze Li, Cindy Zhang, Rong Deng, Douglas Leipold, Dongwei Li, Brandon Latifi, Yuying Gao, Crystal Zhang, Zao Li, Dale Miles, Shang‐Chiung Chen, Divya Samineni, Bei Wang, Priya Agarwal, Dan Lu, Saileta Prabhu, Sandhya Girish & Amrita V. Kamath. (2019) Prediction of Human Pharmacokinetics of Antibody–Drug Conjugates From Nonclinical Data. Clinical and Translational Science 12:5, pages 534-544.
Crossref
Crossref
Cheng Zhang, Xiaofeng Wang, Hua Zhang, Chenjiang Yao, Hao Pan, Yong Guo, Kesuo Fan & Shuqian Jing. (2019) Therapeutic Monoclonal Antibody Antagonizing Endothelin Receptor A for Pulmonary Arterial Hypertension. Journal of Pharmacology and Experimental Therapeutics 370:1, pages 54-61.
Crossref
Crossref
Maria Gabriella Matera, Luigino Calzetta, Paola Rogliani & Mario Cazzola. (2019) Monoclonal antibodies for severe asthma: Pharmacokinetic profiles. Respiratory Medicine 153, pages 3-13.
Crossref
Crossref
Rüdiger Nave, Stefan Jodl, Anja Hoffmann, Isabella Gashaw, Frank Zollmann, Matthias Berse, Joachim Höchel, Jörn Krätzschmar & Beate Rohde. (2019) Monoclonal Antibody Against Prolactin Receptor: A Randomized Placebo-Controlled Study Evaluating Safety, Tolerability, and Pharmacokinetics of Repeated Subcutaneous Administrations in Postmenopausal Women. Reproductive Sciences 26:4, pages 523-531.
Crossref
Crossref
Brandon Bumbaca, Zhe Li & Dhaval K. Shah. (2019) Pharmacokinetics of protein and peptide conjugates. Drug Metabolism and Pharmacokinetics 34:1, pages 42-54.
Crossref
Crossref
Kenta Haraya, Tatsuhiko Tachibana & Tomoyuki Igawa. (2019) Improvement of pharmacokinetic properties of therapeutic antibodies by antibody engineering. Drug Metabolism and Pharmacokinetics 34:1, pages 25-41.
Crossref
Crossref
Timothy Jenkins, Thomas Fryer, Rasmus Dehli, Jonas Jürgensen, Albert Fuglsang-Madsen, Sofie Føns & Andreas Laustsen. (2019) Toxin Neutralization Using Alternative Binding Proteins. Toxins 11:1, pages 53.
Crossref
Crossref
Konstantinos Biliouris, Ivan Nestorov, Himanshu Naik, David Dai, Guangqing Xiao, Qin Wang, Alex Pellerin, Dania Rabah, Lawrence J. Lesko & Mirjam N. Trame. (2018) A pre-clinical quantitative model predicts the pharmacokinetics/pharmacodynamics of an anti-BDCA2 monoclonal antibody in humans. Journal of Pharmacokinetics and Pharmacodynamics 45:6, pages 817-827.
Crossref
Crossref
Amy Hemperly, William J Sandborn & Niels Vande Casteele. (2018) Clinical Pharmacology in Adult and Pediatric Inflammatory Bowel Disease. Inflammatory Bowel Diseases 24:12, pages 2527-2542.
Crossref
Crossref
Meric Ovacik & Kedan Lin. (2018) Tutorial on Monoclonal Antibody Pharmacokinetics and Its Considerations in Early Development. Clinical and Translational Science 11:6, pages 540-552.
Crossref
Crossref
Amy Hemperly & Niels Vande Casteele. (2018) Clinical Pharmacokinetics and Pharmacodynamics of Infliximab in the Treatment of Inflammatory Bowel Disease. Clinical Pharmacokinetics 57:8, pages 929-942.
Crossref
Crossref
Dalia Millán-Gómez, Salvador Dueñas, Patricia L.A. Muñoz, Tanya Camacho-Villegas, Carolina Elosua, Olivia Cabanillas-Bernal, Teresa Escalante, Almudena Perona, David Abia, Florian Drescher, Pierrick G.J. Fournier, Marco A. Ramos, Rosa E. Mares, Jorge Paniagua-Solis, Teresa Mata-Gonzalez, Jorge Gonzalez-Canudas, Robert M. Hoffman, Alexei Licea-Navarro & Noemí Sánchez-Campos. (2018)
In silico-designed
mutations increase variable new-antigen receptor single-domain antibodies for VEGF165 neutralization
. Oncotarget 9:46, pages 28016-28029.
Crossref
Crossref
Andreas H. Laustsen, José María Gutiérrez, Cecilie Knudsen, Kristoffer H. Johansen, Erick Bermúdez-Méndez, Felipe A. Cerni, Jonas A. Jürgensen, Line Ledsgaard, Andrea Martos-Esteban, Mia Øhlenschlæger, Urska Pus, Mikael R. Andersen, Bruno Lomonte, Mikael Engmark & Manuela B. Pucca. (2018) Pros and cons of different therapeutic antibody formats for recombinant antivenom development. Toxicon 146, pages 151-175.
Crossref
Crossref
Rong Deng, Ai Ping Lee, Mauricio Maia, Jeremy J. Lim, Tracy Burgess, Priscilla Horn, Michael A. Derby, Elizabeth Newton, Jorge A. Tavel & William D. Hanley. (2017) Pharmacokinetics of MHAA4549A, an Anti-Influenza A Monoclonal Antibody, in Healthy Subjects Challenged with Influenza A Virus in a Phase IIa Randomized Trial. Clinical Pharmacokinetics 57:3, pages 367-377.
Crossref
Crossref
Rosa Bustos, Carlos Zapata, Efraín Esteban, Julio-César García, Edwin Jáuregui & Diego Jaimes. (2018) Label-Free Quantification of Anti-TNF-α in Patients Treated with Adalimumab Using an Optical Biosensor. Sensors 18:3, pages 691.
Crossref
Crossref
Matts Kågedal, Leonid Gibiansky, Jian Xu, Xin Wang, Divya Samineni, Shang-Chiung Chen, Dan Lu, Priya Agarwal, Bei Wang, Ola Saad, Neelima Koppada, Bernard M. Fine, Jin Y. Jin, Sandhya Girish & Chunze Li. (2017) Platform model describing pharmacokinetic properties of vc-MMAE antibody–drug conjugates. Journal of Pharmacokinetics and Pharmacodynamics 44:6, pages 537-548.
Crossref
Crossref
Jacqueline M. McBride, Jeremy J. Lim, Tracy Burgess, Rong Deng, Michael A. Derby, Mauricio Maia, Priscilla Horn, Omer Siddiqui, Daniel Sheinson, Haiyin Chen-Harris, Elizabeth M. Newton, Dimitri Fillos, Denise Nazzal, Carrie M. Rosenberger, Maikke B. Ohlson, Rob Lambkin-Williams, Hosnieh Fathi, Jeffrey M. Harris & Jorge A. Tavel. (2017) Phase 2 Randomized Trial of the Safety and Efficacy of MHAA4549A, a Broadly Neutralizing Monoclonal Antibody, in a Human Influenza A Virus Challenge Model. Antimicrobial Agents and Chemotherapy 61:11.
Crossref
Crossref
Jennifer Sheng, Shivani Srivastava, Kinjal Sanghavi, Zheng Lu, Brian J. Schmidt, Akintunde Bello & Manish Gupta. (2017) Clinical Pharmacology Considerations for the Development of Immune Checkpoint Inhibitors. The Journal of Clinical Pharmacology 57, pages S26-S42.
Crossref
Crossref
M Cavaco & J Goncalves. (2017) Interactions Between Therapeutic Proteins and Small Molecules: The Shared Role of Perpetrators and Victims. Clinical Pharmacology & Therapeutics 102:4, pages 649-661.
Crossref
Crossref
Sreeja Gopal, Shobha Purushothama, Alvydas Mikulskis & Lauren Stevenson. (2017) Development of a plug and play ImmunoPCR technique for the analysis of biomolecules. Bioanalysis 9:17, pages 1293-1303.
Crossref
Crossref
Josiah T. Ryman & Bernd Meibohm. (2017) Pharmacokinetics of Monoclonal Antibodies. CPT: Pharmacometrics & Systems Pharmacology 6:9, pages 576-588.
Crossref
Crossref
Long Yuan & Qin C. Ji. 2017. Protein Analysis using Mass Spectrometry. Protein Analysis using Mass Spectrometry
203
220
.
Yang Chen & Yan Xu. (2017) Pharmacokinetics of Bispecific Antibody. Current Pharmacology Reports 3:3, pages 126-137.
Crossref
Crossref
Xiang-Qing Yu, Gabriel J. Robbie, Yuling Wu, Mark T. Esser, Kathryn Jensen, Howard I. Schwartz, Terramika Bellamy, Martha Hernandez-Illas & Hasan S. Jafri. (2017) Safety, Tolerability, and Pharmacokinetics of MEDI4893, an Investigational, Extended-Half-Life, Anti-Staphylococcus aureus Alpha-Toxin Human Monoclonal Antibody, in Healthy Adults. Antimicrobial Agents and Chemotherapy 61:1.
Crossref
Crossref
Amrita V. Kamath. 2016. Antibody‐Drug Conjugates. Antibody‐Drug Conjugates
245
266
.
Gaurav Goel, Aman Chauhan & Peter J. Hosein. (2016) Ramucirumab: a Novel Anti-Angiogenic Agent in the Treatment of Metastatic Colorectal Cancer. Current Colorectal Cancer Reports 12:5, pages 232-240.
Crossref
Crossref
Jeremy J. Lim, Rong Deng, Michael A. Derby, Richard Larouche, Priscilla Horn, Malia Anderson, Mauricio Maia, Stephanie Carrier, Isabelle Pelletier, Tracy Burgess, Priya Kulkarni, Elizabeth Newton & Jorge A. Tavel. (2016) Two Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Studies To Investigate the Safety, Tolerability, and Pharmacokinetics of an Anti-Influenza A Virus Monoclonal Antibody, MHAA4549A, in Healthy Volunteers. Antimicrobial Agents and Chemotherapy 60:9, pages 5437-5444.
Crossref
Crossref
Amrita V. Kamath. (2016) Translational pharmacokinetics and pharmacodynamics of monoclonal antibodies. Drug Discovery Today: Technologies 21-22, pages 75-83.
Crossref
Crossref
Amrita V. Kamath & Suhasini Iyer. (2015) Challenges and advances in the assessment of the disposition of antibody‐drug conjugates. Biopharmaceutics & Drug Disposition 37:2, pages 66-74.
Crossref
Crossref
Jing Wang, Suhasini Iyer, Paul J. Fielder, John D. Davis & Rong Deng. (2015) Projecting human pharmacokinetics of monoclonal antibodies from nonclinical data: comparative evaluation of prediction approaches in early drug development. Biopharmaceutics & Drug Disposition 37:2, pages 51-65.
Crossref
Crossref
Finn Sellebjerg, Diego Cadavid, Deborah Steiner, Luisa Maria Villar, Richard Reynolds & Daniel Mikol. (2015) Exploring potential mechanisms of action of natalizumab in secondary progressive multiple sclerosis. Therapeutic Advances in Neurological Disorders 9:1, pages 31-43.
Crossref
Crossref
Guy M.L. Meno‐Tetang. 2010. Pharmaceutical Sciences Encyclopedia. Pharmaceutical Sciences Encyclopedia
1
12
.
Songmao Zheng, Weirong Wang & Honghui Zhou. 2010. Pharmaceutical Sciences Encyclopedia. Pharmaceutical Sciences Encyclopedia
1
22
.
Dietmar Reusch & Max L Tejada. (2015) Fc glycans of therapeutic antibodies as critical quality attributes. Glycobiology 25:12, pages 1325-1334.
Crossref
Crossref
Chao Gong, Naiyu Zheng, Jianing Zeng, Anne-Françoise Aubry & Mark E. Arnold. (2015) Post-pellet-digestion precipitation and solid phase extraction: A practical and efficient workflow to extract surrogate peptides for ultra-high performance liquid chromatography – tandem mass spectrometry bioanalysis of a therapeutic antibody in the low ng/mL range. Journal of Chromatography A 1424, pages 27-36.
Crossref
Crossref
Lei ZhengMark Milton. 2015. Monoclonal Antibodies: Development, Delivery and Applications. Monoclonal Antibodies: Development, Delivery and Applications
58
82
.
Amrita V. Kamath & Suhasini Iyer. (2014) Preclinical Pharmacokinetic Considerations for the Development of Antibody Drug Conjugates. Pharmaceutical Research 32:11, pages 3470-3479.
Crossref
Crossref
Dhaval K. Shah. (2015) Pharmacokinetic and pharmacodynamic considerations for the next generation protein therapeutics. Journal of Pharmacokinetics and Pharmacodynamics 42:5, pages 553-571.
Crossref
Crossref
Julie H. Ishida, Tracy Burgess, Michael A. Derby, Pearline A. Brown, Mauricio Maia, Rong Deng, Brinda Emu, Becket Feierbach, Ashley E. Fouts, X. Charlene Liao & Jorge A. Tavel. (2015) Phase 1 Randomized, Double-Blind, Placebo-Controlled Study of RG7667, an Anticytomegalovirus Combination Monoclonal Antibody Therapy, in Healthy Adults. Antimicrobial Agents and Chemotherapy 59:8, pages 4919-4929.
Crossref
Crossref
Johannes Wohlrab. (2015) Pharmakokinetische Besonderheiten von therapeutischen Antikörpern. JDDG: Journal der Deutschen Dermatologischen Gesellschaft 13:6, pages 530-534.
Crossref
Crossref
Johannes Wohlrab. (2015) Pharmacokinetic characteristics of therapeutic antibodies. JDDG: Journal der Deutschen Dermatologischen Gesellschaft 13:6, pages 530-534.
Crossref
Crossref
Long Yuan & Mingshe Zhu. (2015) Quantitative Bioanalysis of Proteins by Mass Spectrometry. Materials and Methods 5.
Crossref
Crossref
Songmao Zheng, Thomas McIntosh & Weirong Wang. (2015) Utility of free and total target measurements as target engagement and efficacy biomarkers in biotherapeutic development-Opportunities and challenges. The Journal of Clinical Pharmacology 55:S3, pages S75-S84.
Crossref
Crossref
K. R. Henne, B. Ason, M. Howard, W. Wang, J. Sun, J. Higbee, J. Tang, K. C. Matsuda, R. Xu, L. Zhou, J. C. Y. Chan, C. King, D. E. Piper, R. R. Ketchem, M. L. Michaels, S. M. Jackson & M. W. Retter. (2015) Anti-PCSK9 Antibody Pharmacokinetics and Low-Density Lipoprotein-Cholesterol Pharmacodynamics in Nonhuman Primates Are Antigen Affinity-Dependent and Exhibit Limited Sensitivity to Neonatal Fc Receptor-Binding Enhancement. Journal of Pharmacology and Experimental Therapeutics 353:1, pages 119-131.
Crossref
Crossref
Manoranjenni Chetty, Linzhong Li, Rachel Rose, Krishna Machavaram, Masoud Jamei, Amin Rostami-Hodjegan & Iain Gardner. (2015) Prediction of the Pharmacokinetics, Pharmacodynamics, and Efficacy of a Monoclonal Antibody, Using a Physiologically Based Pharmacokinetic FcRn Model. Frontiers in Immunology 5.
Crossref
Crossref
Siddharth Sukumaran & Kedan Lin.. 2015. Antibody-Drug Conjugates. Antibody-Drug Conjugates
117
131
.
Xingxing WangKazim YigitkanliChang-Yeon KimTomoko Sekine-KonnoDana WirakEric FriedenAjay BhargavaGeorge MaynardWilliam B.J. CaffertyStephen M. Strittmatter. (2014) Human NgR-Fc Decoy Protein via Lumbar Intrathecal Bolus Administration Enhances Recovery from Rat Spinal Cord Contusion. Journal of Neurotrauma 31:24, pages 1955-1966.
Crossref
Crossref
Michael P. Hall. (2014) Biotransformation and In Vivo Stability of Protein Biotherapeutics: Impact on Candidate Selection and Pharmacokinetic Profiling. Drug Metabolism and Disposition 42:11, pages 1873-1880.
Crossref
Crossref
Jan Willem van der Laan, Carla Herberts, David Jones, Susan J Thorpe, Richard Stebbings & Robin Thorpe. 2014. Molecular Immunotoxicology. Molecular Immunotoxicology
189
208
.
Jonathan Q. TranJitesh RanaFrederik BarkhofIsaac MelamedHakop GevorkyanMike P. WattjesRemko de JongKristin BrosofskySoma RayLei XuJim ZhaoEdward ParrDiego Cadavid. (2014) Randomized phase I trials of the safety/tolerability of anti-LINGO-1 monoclonal antibody BIIB033. Neurology Neuroimmunology & Neuroinflammation 1:2.
Crossref
Crossref
Weirong Wang, Xiaofeng Wang, Rajitha Doddareddy, Damien Fink, Thomas McIntosh, Hugh M. Davis & Honghui Zhou. (2013) Mechanistic Pharmacokinetic/Target Engagement/Pharmacodynamic (PK/TE/PD) Modeling in Deciphering Interplay Between a Monoclonal Antibody and Its Soluble Target in Cynomolgus Monkeys. The AAPS Journal 16:1, pages 129-139.
Crossref
Crossref
Long YuanAnne-Françoise Aubry, Mark E Arnold & Qin C Ji. (2013) Systematic investigation of orthogonal SPE sample preparation for the LC–MS/MS bioanalysis of a monoclonal antibody after pellet digestion. Bioanalysis 5:19, pages 2379-2391.
Crossref
Crossref
Wendy W. Cai, Michele Fiscella, Cecil Chen, Z. John Zhong, William W. Freimuth & David C. Subich. (2013) Bioavailability, Pharmacokinetics, and Safety of Belimumab Administered Subcutaneously in Healthy Subjects. Clinical Pharmacology in Drug Development 2:4, pages 349-357.
Crossref
Crossref
Raymond Evers, Shannon Dallas, Leslie J. Dickmann, Odette A. Fahmi, Jane R. Kenny, Eugenia Kraynov, Theresa Nguyen, Aarti H. Patel, J. Greg Slatter & Lei Zhang. (2013) Critical Review of Preclinical Approaches to Investigate Cytochrome P450–Mediated Therapeutic Protein Drug-Drug Interactions and Recommendations for Best Practices: A White Paper. Drug Metabolism and Disposition 41:9, pages 1598-1609.
Crossref
Crossref
Hans C. Ebbers, Peter J.K. van Meer, Ellen H.M. Moors, Aukje K. Mantel-Teeuwisse, Hubert G.M. Leufkens & Huub Schellekens. (2013) Measures of biosimilarity in monoclonal antibodies in oncology: the case of bevacizumab. Drug Discovery Today 18:17-18, pages 872-879.
Crossref
Crossref
Leijun Hu & Ryan J. Hansen. (2013) Issues, challenges, and opportunities in model-based drug development for monoclonal antibodies. Journal of Pharmaceutical Sciences 102:9, pages 2898-2908.
Crossref
Crossref
Jean W Lee. (2013) ADME of monoclonal antibody biotherapeutics: knowledge gaps and emerging tools. Bioanalysis 5:16, pages 2003-2014.
Crossref
Crossref
Miroslav Dostalek, Iain Gardner, Brian M. Gurbaxani, Rachel H. Rose & Manoranjenni Chetty. (2013) Pharmacokinetics, Pharmacodynamics and Physiologically-Based Pharmacokinetic Modelling of Monoclonal Antibodies. Clinical Pharmacokinetics 52:2, pages 83-124.
Crossref
Crossref
Melinda Marian & Wolfgang Seghezzi. 2013. Nonclinical Development of Novel Biologics, Biosimilars, Vaccines and Specialty Biologics. Nonclinical Development of Novel Biologics, Biosimilars, Vaccines and Specialty Biologics
97
137
.
Kedan Lin, Jay Tibbitts & Ben-Quan Shen. 2013. Antibody-Drug Conjugates. Antibody-Drug Conjugates
117
131
.
Long Yuan, Mark E Arnold, Anne-Françoise Aubry & Qin C Ji. (2012) Simple and efficient digestion of a monoclonal antibody in serum using pellet digestion: comparison with traditional digestion methods in LC–MS/MS bioanalysis. Bioanalysis 4:24, pages 2887-2896.
Crossref
Crossref
Daniela Bumbaca, C. Andrew Boswell, Paul J. Fielder & Leslie A. Khawli. (2012) Physiochemical and Biochemical Factors Influencing the Pharmacokinetics of Antibody Therapeutics. The AAPS Journal 14:3, pages 554-558.
Crossref
Crossref